MOG (35-55) TFA (Synonyms: Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat TFA)

Name: MOG (35-55) TFA
Brand: MedChemExpress
SKU: HY-P1240A
Rating: 5.0 (9 reviews)

Cat. No.: HY-P1240A Purity: 99.68%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

MOG (35-55) (MOG (35-55)) TFA is a minor component of CNS myelin. MOG (35-55) (TFA) has encephalitogenic activity and induces T cell proliferative. MOG (35-55) (TFA) induces Th1 cytokine response as well as relatively high levels of IgG antibodies. MOG (35-55) (TFA) produces a relapsing-remitting neurological disease with extensive plaque-like demyelination. MOG (35-55) (MOG (35-55)) TFA can be used for experimental autoimmune encephalomyelitis (EAE) modeling.

For research use only. We do not sell to patients.

Custom Peptide Synthesis

Size	Stock	Quantity
5 mg	In-stock	Estimated Time of Arrival: December 31
10 mg	In-stock	Estimated Time of Arrival: December 31
50 mg	Get quote
100 mg	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 9 publication(s) in Google Scholar

Other Forms of MOG (35-55) TFA:

MOG (35-55) mouse, rat In-stock
MOG (35-55) acetate In-stock

9 Publications Citing Use of MCE MOG (35-55) TFA

Others

Cell Proliferation/Viability Assay

Histological Imaging/Staining

ELISA

Flow Cytometry

: MOG (35-55) TFA purchased from MedChemExpress. Usage Cited in: EMBO Mol Med. 2025 Sep 29. [Abstract]; Scheme of the EAE Adoptive Transfer Model: Mice underwent immunization via subcutaneous injection of MOG35–55 in complete Freund’s adjuvant. Ten days post-immunization, spleens were harvested, and single-cell suspensions were prepared. These splenocytes were treated for 3 days with IL-12, IL-23, and anti-IFN-γ. Subsequently, the splenocytes were subjected to a 3-day treatment with 1 μM PAPTP, or left untreated. Antigen-specificity of the cells was confirmed by additional proliferation assays of isolated donor lymphocytes (see Methods). Lymphocytes were isolated, and the induction of apoptosis was assessed using flow cytometry. Additionally, these lymphocytes were transferred into wild-type recipient animals, and the animals’ clinical scores were monitored daily for 10 days. Following the observation period, the animals were euthanized for further analysis.

: MOG (35-55) TFA purchased from MedChemExpress. Usage Cited in: EMBO Mol Med. 2025 Sep 29. [Abstract]; Representative image (of 5 sections) of brains (upper part of the pons region) stained with PE-anti-CD45, from wild-type mice intraperitoneally injected with either untreated or PAPTP 1 μM treated, MOG35–55 activated lymphocytes.3J

: MOG (35-55) TFA purchased from MedChemExpress. Usage Cited in: EMBO Mol Med. 2025 Sep 29. [Abstract]; Treatment scheme for wild-type mice immunized via subcutaneous injection of MOG35–55: upon the manifestation of initial symptoms, typically around day 10 post-immunization, treatment commenced. The treatment regimen was administered every 48 h, totaling 11 injections. Mice were euthanized the day following the final injection for subsequent analysis of peripheral blood, brains, and spinal cords.

: MOG (35-55) TFA purchased from MedChemExpress. Usage Cited in: Front Biosci (Landmark Ed). 2025 May 23;30(5):37838. [Abstract]; The BV-2 cells were cultured in designated concentrations of MOG35-55 (0-25μg/mL, 24 h). MTT analysis of BV-2 cell viability.

: MOG (35-55) TFA purchased from MedChemExpress. Usage Cited in: Front Biosci (Landmark Ed). 2025 May 23;30(5):37838. [Abstract]; The BV-2 cells were cultured in designated concentrations of MOG35-55 (0-25μg/mL, 24 h). ELISA analysis of the release of HMGB1.

: MOG (35-55) TFA purchased from MedChemExpress. Usage Cited in: Front Biosci (Landmark Ed). 2025 May 23;30(5):37838. [Abstract]; The BV-2 cells were cultured in designated concentrations of MOG35-55 (0-25μg/mL). Cytometry analysis for CD11b⁺ and CD68⁺ cells.

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Endogenous Metabolite Isoform Specific Products:

View All Isoforms

Human Endogenous Metabolite Microbial Metabolite

Biological Activity
Purity & Documentation
References
Customer Review

Description

In Vitro

MOG (35-55) (MOG (35-55); 0-50 μg/mL; 72 h; lymph nodes cells) TFA induces T cell proliferative and secretes Th1 cytokines including IFN-γ, TNF-α, IL-10, IL-4 and IL-5. MOG (35-55) (TFA) increases the level of IgG^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Note:
Please do not refer to only one article to determine the experimental conditions. It is recommended to determine the optimal experimental conditions (animal strain, age, dosage, frequency and cycle, detection time and indicators, etc.) through preliminary experiments before the formal experiment.

Myelin oligodendrocyte glycoprotein (MOG) peptide 35-55 is one of the targets of self-reactive T cell responses, leading to acute and later chronic autoimmune processes. MOG 35-55 is capable of inducing experimental autoimmune encephalomyelitis (EAE) in B6 mice^[1].

Induction of experimental autoimmune encephalomyelitis (EAE) model^[3]

Background

MOG (35-55) CAN trigger an immune response against the CNS, and induces inflammation and destruction of myelin or antigen-bearing structures that causes neurological abnormalities.

Specific Modeling Methods

Mice: C57BL/6 background mice • 2-4 months old • male and female
Administration: On day 0: 3 mg/mL peptide plus CFA (4 mg/mL) • Mix thoroughly 1: 1 peptide and CFA solutions • s.c. • 100 μL for each hind flank; • On day 0 and day 2: 2.5 μg/mL of Bordetella pertussis toxin • i.p. • 200 μL

Note

1. Once peptide and CFA emulsion is formed, it can be stored at 4 °C for a few hours or used immediately.
2. Symptoms appear approximately 10-15 days after immunization.
3. When mice have clinical symptoms of EAE, hydrated food is placed on the cage floor to facilitate access to these mice.
4. Record parameters every other day at the beginning, and daily from 7th postimmunization day. Body weight decreases usually precedes EAE clinical signs and is a very objective and valuable measure.

Modeling Indicators

Evaluate changes in body weight and clinical scoring: body weight loss, loss of tail tonus, paralyzed tail, hind limb paraparesis, hind limb paralysis, front leg paralysis, tetraplegia, moribund, etc.
prototypical histopathological changes: Luxol fast blue staining of spinal cord for myelin evaluation shows infiltrates and demyelination in EAE animals.

Correlated Product(s): Complete Freund's adjuvant (CFA) (HY-153808)

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	HLA-DR2 (DRB1*1501) mice^[1]
Dosage:	200 μg (0.2 mL)
Administration:	Intraperitoneal injection; once, for 38 days
Result:	Resulted in paralysis of both hind and forelimbs.

Molecular Weight

2695.97

Formula

C₁₂₀H₁₇₈F₃N₃₅O₃₁S

Appearance

Solid

Color

White to off-white

Sequence

Met-Glu-Val-Gly-Trp-Tyr-Arg-Ser-Pro-Phe-Ser-Arg-Val-Val-His-Leu-Tyr-Arg-Asn-Gly-Lys

Sequence Shortening

MEVGWYRSPFSRVVHLYRNGK

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Sealed storage, away from moisture and light, under nitrogen

Powder	-80°C	2 years
	-20°C	1 year

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen)

Solvent & Solubility

In Vitro:

H₂O : ≥ 50 mg/mL (18.55 mM)

DMSO : 2 mg/mL (0.74 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	0.3709 mL	1.8546 mL	3.7092 mL
5 mM	0.0742 mL	0.3709 mL	0.7418 mL
10 mM	0.0371 mL	0.1855 mL	0.3709 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: PBS
Solubility: 100 mg/mL (37.09 mM); Clear solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Calculation results:

Working solution concentration: mg/mL

This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact MedChemExpress (MCE).

Purity & Documentation

Purity: 99.68%

Select Batch:

Data Sheet (285 KB) SDS (252 KB)

COA (254 KB) RP-HPLC (237 KB) MS (73 KB) Elemental Analysis Report (113 KB)

Handling Instructions (2659 KB)

References

[1]. Rich C, et, al. Myelin oligodendrocyte glycoprotein-35-55 peptide induces severe chronic experimental autoimmune encephalomyelitis in HLA-DR2-transgenic mice. Eur J Immunol. 2004 May;34(5):1251-61. [Content Brief]

[2]. Slavin A, et, al. Induction of a multiple sclerosis-like disease in mice with an immunodominant epitope of myelin oligodendrocyte glycoprotein. Autoimmunity. 1998;28(2):109-20. [Content Brief]

[3]. Giralt M, et, al. Active Induction of Experimental Autoimmune Encephalomyelitis (EAE) with MOG35-55 in the Mouse. Methods Mol Biol. 2018;1791:227-232. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

H₂O	1 mM	0.3709 mL	1.8546 mL	3.7092 mL	9.2731 mL
	5 mM	0.0742 mL	0.3709 mL	0.7418 mL	1.8546 mL
	10 mM	0.0371 mL	0.1855 mL	0.3709 mL	0.9273 mL
	15 mM	0.0247 mL	0.1236 mL	0.2473 mL	0.6182 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

MOG (35-55) TFA Related Classifications

Neurological Disease Inflammation/Immunology

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

MOG (35-55)Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, ratEndogenous MetaboliteautoantigenicdemyelinatingplaqueautoimmunityInhibitorinhibitorinhibit

Your Recently Viewed Products:

Product Name

Requested Quantity *

Applicant Name *

Salutation

Email Address *

Phone Number *

Department

Organization Name *

City

State

Country or Region *

Remarks

Product Name

Lot #

Applicant Name *

Email Address *

Phone Number

Department *

Organization Name *

Country or Region *

Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

MOG (35-55) TFA (Synonyms: Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat TFA)

Customer Review

Other Forms of MOG (35-55) TFA:

MOG (35-55) TFA Related Antibodies

9 Publications Citing Use of MCE MOG (35-55) TFA

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Endogenous Metabolite Isoform Specific Products:

Biological Activity

Purity & Documentation

References

Customer Review

MOG (35-55) TFA Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

MOG (35-55) TFA Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report